Countering a Recent GEN Article Author Believes the Prevailing Business Strategy Is Valid Gary P. Pisano’s contribution to the Point of View column in the April 15 issue of GEN argues that “… the ...
The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #17 is a biotech by the name of Tempest Therapeutics (TPST). I want to state that I have chosen to ...
The next article I wanted to discuss for the Biotech Analysis Central Model 10+ Portfolio Old Pick #4 is a biotech by the name of Cardiff Oncology (CRDF). The reason why I wanted to go over this ...
Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
The subtitle of Michael Sable, Ph.D.’s Point of View column in the September 15 issue of GEN, “Current patent policies stymie innovation and are detrimental to the well-being of societies,” summarizes ...
News-Medical.Net on MSN
Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models
Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel ...
The latest report on the global biotechnology sector from Ernst & Young notes that the sector enjoyed "showed a second straight year of increasingly stable financial performance in 2011", but ...
Explore the shipping of organoid models with Atelerix and Cherry Biotech's innovative collaboration for improved transport ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback